9 results on '"Luzio S"'
Search Results
2. Safety of the use of gold nanoparticles conjugated with proinsulin peptide and administered by hollow microneedles as an immunotherapy in type 1 diabetes
- Author
-
Tatovic, D, primary, McAteer, M A, additional, Barry, J, additional, Barrientos, A, additional, Rodríguez Terradillos, K, additional, Perera, I, additional, Kochba, E, additional, Levin, Y, additional, Dul, M, additional, Coulman, S A, additional, Birchall, J C, additional, von Ruhland, C, additional, Howell, A, additional, Stenson, R, additional, Alhadj Ali, M, additional, Luzio, S D, additional, Dunseath, G, additional, Cheung, W Y, additional, Holland, G, additional, May, K, additional, Ingram, J R, additional, Chowdhury, M M U, additional, Wong, F S, additional, Casas, R, additional, Dayan, C, additional, and Ludvigsson, J, additional
- Published
- 2022
- Full Text
- View/download PDF
3. Ustekinumab for type 1 diabetes in adolescents: a multicenter, double-blind, randomized phase 2 trial.
- Author
-
Tatovic D, Marwaha A, Taylor P, Hanna SJ, Carter K, Cheung WY, Luzio S, Dunseath G, Hutchings HA, Holland G, Hiles S, Fegan G, Williams E, Yang JHM, Domingo-Vila C, Pollock E, Wadud M, Ward-Hartstonge K, Marques-Jones S, Bowen-Morris J, Stenson R, Levings MK, Gregory JW, Tree TIM, and Dayan C
- Subjects
- Humans, Adolescent, Double-Blind Method, Child, Female, Male, C-Peptide metabolism, Interleukin-17 immunology, Th17 Cells immunology, Th17 Cells drug effects, Insulin-Secreting Cells drug effects, Treatment Outcome, Diabetes Mellitus, Type 1 drug therapy, Diabetes Mellitus, Type 1 immunology, Ustekinumab therapeutic use
- Abstract
Immunotherapy targeting the autoimmune process in type 1 diabetes (T1D) can delay the loss of β-cells but needs to have minimal adverse effects to be an adjunct to insulin in the management of T1D. Ustekinumab binds to the shared p40 subunit of interleukin (IL)-12 and IL-23, targeting development of T helper 1 cells and T helper 17 cells (T
H 1 and TH 17 cells) implicated in the pathogenesis of T1D. We conducted a double-blind, randomized controlled trial of ustekinumab in 72 adolescents aged 12-18 years with recent-onset T1D. Treatment was well tolerated with no increase in adverse events. At 12 months, β-cell function, measured by stimulated C-peptide, was 49% higher in the intervention group (P = 0.02), meeting the prespecified primary outcome. Preservation of C-peptide correlated with the reduction of T helper cells co-secreting IL-17A and interferon-γ (TH 17.1 cells, P = 0.04) and, in particular, with the reduction in a subset of TH 17.1 cells co-expressing IL-2 and granulocyte-macrophage colony-stimulating factor (IL-2+ GM-CSF+ TH 17.1 cells, P = 0.04). A significant fall in β-cell-targeted (proinsulin-specific) IL-17A-secreting T cells was also seen (P = 0.0003). Although exploratory, our data suggest a role for an activated subset of TH 17.1 cells in T1D that can be targeted with minimal adverse effects to reduce C-peptide loss, which requires confirmation in a larger study. (International Standard Randomised Controlled Trial Number Registry: ISRCTN 14274380)., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF
4. Using Artificial Intelligence to Improve the Accuracy of a Wrist-Worn, Noninvasive Glucose Monitor: A Pilot Study.
- Author
-
Qureshi MRA, Bain SC, Luzio S, Handy C, Fowles DJ, Love B, Wareham K, Barlow L, Dunseath GJ, Crane J, Masso IC, Ryan JAM, and Chaudhry MS
- Abstract
Background: Self-monitoring of glucose is important to the successful management of diabetes; however, existing monitoring methods require a degree of invasive measurement which can be unpleasant for users. This study investigates the accuracy of a noninvasive glucose monitoring system that analyses spectral variations in microwave signals., Methods: An open-label, pilot design study was conducted with four cohorts (N = 5/cohort). In each session, a dial-resonating sensor (DRS) attached to the wrist automatically collected data every 60 seconds, with a novel artificial intelligence (AI) model converting signal resonance output to a glucose prediction. Plasma glucose was measured in venous blood samples every 5 minutes for Cohorts 1 to 3 and every 10 minutes for Cohort 4. Accuracy was evaluated by calculating the mean absolute relative difference (MARD) between the DRS and plasma glucose values., Results: Accurate plasma glucose predictions were obtained across all four cohorts using a random sampling procedure applied to the full four-cohort data set, with an average MARD of 10.3%. A statistical analysis demonstrates the quality of these predictions, with a surveillance error grid (SEG) plot indicating no data pairs falling into the high-risk zones., Conclusions: These findings show that MARD values approaching accuracies comparable to current commercial alternatives can be obtained from a multiparticipant pilot study with the application of AI. Microwave biosensors and AI models show promise for improving the accuracy and convenience of glucose monitoring systems for people with diabetes., Competing Interests: Declaration of Conflicting InterestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: MRAQ, CH, DJF, BL, ICM, and JAMR are employees of Afon Technology, and MSC is the chief executive officer of Afon Technology.
- Published
- 2024
- Full Text
- View/download PDF
5. Quantifying cardiovascular disease risk and heart age predictions for men in the prison environment.
- Author
-
Gray BJ, Craddock C, Couzens Z, Dunseath GJ, Shankar AG, Luzio SD, and Perrett SE
- Subjects
- Humans, Male, Cross-Sectional Studies, Prisons, Risk Factors, Risk Assessment, Cardiovascular Diseases epidemiology, Cardiovascular Diseases prevention & control
- Abstract
Objectives: Cardiovascular disease (CVD) and associated risk factors within the prison population often present at a younger age in this cohort. Given CVD is largely preventable, it warrants investigation to fully quantify this risk. This study explored the relative predicted 10-year CVD risk and examined the calculated heart age in a representative sample of male individuals aged 25-84 years within the prison environment., Study Design: This was a cross-sectional study., Methods: Data were collected on 299 men who underwent a cardiometabolic risk assessment in HMP Parc, Bridgend. The QRISK2 algorithm was used to calculate 10-year CVD risk, relative risk (to general population) and the predicted heart age of an individual. Between-group differences (prison population vs general community) in cardiovascular risk predictions (10-year CVD risk and heart age) were assessed., Results: We observed that at all age groups, the relative risk of predicted 10-year CVD scores in the prison population was double that of the community risk (2.1 ± 0.6), and this was most apparent in the oldest age group (≥50 years: 17.0% compared to 8.8%; P < 0.001). Overall, the heart age of the sample was 7.5 (6.7-8.2) years higher than their own chronological age, and this difference increased to above 9 years in those aged ≥40 years., Conclusions: This study provides quantifiable evidence to the elevated CVD risk in prison. Heart age predictions were almost a decade higher in those aged ≥40 years. Lowering the screening age for CVD by around 5 years in the prison population should be considered., (Copyright © 2023 The Royal Society for Public Health. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
6. Obesity in Childhood and Adolescence: The Role of Motivation for Physical Activity, Self-Esteem, Implicit and Explicit Attitudes toward Obesity and Physical Activity.
- Author
-
Scotto di Luzio S, Martinent G, Popa-Roch M, Ballereau M, Chahdi S, Escudero L, and Guillet-Descas E
- Abstract
The purpose of the present study was to compare attitudes toward body weight and physical activity in both regular-weight and overweight/obese children and adolescents, and assessing relations between attitudes and self-esteem, motivation for physical activity, life satisfaction and level of physical activity. A total of 126 children (Mage = 12.2, SD = 3.4), divided into two subsamples (i.e., overweight/obese, N = 44, and regular-weight), voluntarily participated in the study. A series of univariate analyses of variance was conducted to examine the differences in the study variables across the subsamples. Correlational analyses were conducted to examine the relationships among the variables. The results indicated that obese/overweight participants expressed a more positive implicit attitude toward the thin category than regular-weight participants. Furthermore, among overweight/obese participants, implicit attitude toward physical activity was significantly negatively correlated with explicit attitude toward physical activity and general self-esteem. Significant differences between obese/overweight and regular-weight participants indicated that the status in terms of weight played a key role in attitudes toward the explored constructs.
- Published
- 2023
- Full Text
- View/download PDF
7. Acute postprandial gut hormone, leptin, glucose and insulin responses to resistant starch in obese children: a single blind crossover study.
- Author
-
Suntharesan J, Atapattu N, Jasinghe E, Ekanayake S, de Silva DAGH, Dunseath G, Luzio S, and Premawardhana L
- Subjects
- Child, Humans, Ghrelin, Leptin, Resistant Starch, Cross-Over Studies, Single-Blind Method, Glucose, Coconut Oil, Glucagon-Like Peptide 1, Blood Glucose metabolism, Peptide YY, Meals physiology, Insulin, Pediatric Obesity
- Abstract
Introduction: Resistant starch (RS) has beneficial effects on postprandial glucose metabolism in both animals and adults. Hitherto, there have been no studies in children of the acute metabolic and hormonal effects of RS-containing meals., Objectives: We aimed to compare serial plasma glucose, insulin, gut hormone, leptin profiles and satiety scores in obese children after meals containing variable amounts of RS., Methods: This was a single blind, non-randomised, crossover study of 20 obese children aged 10-14 years old without comorbidities. Three test meals containing rice (M1), rice cooked with coconut oil (M2), rice cooked in coconut oil with lentils (M3) were given in sequence after a 12-hour fast . Blood samples were analysed for glucose (PG), insulin, leptin, glucagon-like polypeptide (GLP) 1, ghrelin and peptide YY (PYY) at appropriate times between 0 and 180 min., Results: Meal M2 resulted in significantly lower postprandial glucose values compared with meal M1 (maximal incremental glucose, ∆C
max , p<0.05; area under the curve, ∆AUC0-3 , p<0.01) and meal M3 (maximal concentration, Cmax , p<0.01; ∆Cmax , p<0.001, and ∆AUC0-3 p<0.01). M2 also produced lower insulin values compared with M1 (p<0.05). Postprandial ghrelin was significantly higher after M1 compared with M3 (p<0.05). PYY, GLP1 and median satiety scores were not significantly different between the three meals., Conclusion: This study shows that M2, the meal containing RS alone, induced beneficial effects on acute postprandial glucose, insulin and ghrelin concentrations in obese children without diabetes. Acute postprandial satiety scores were not significantly affected by the three meals., Trial Registration Number: SLCTR/2020/007., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)- Published
- 2023
- Full Text
- View/download PDF
8. Evaluating the impact of a prison smoking ban on the cardiovascular health of men in a UK prison.
- Author
-
Perrett SE, Craddock C, Dunseath G, Shankar G, Luzio S, and Gray BJ
- Subjects
- Male, Humans, Middle Aged, Aged, Child, Preschool, Child, Prisons, United Kingdom epidemiology, Smoke-Free Policy, Prisoners, Cardiovascular Diseases epidemiology, Cardiovascular Diseases prevention & control
- Abstract
Purpose: Smoking rates are known to be higher amongst those committed to prison than the general population. Those in prison suffer from high rates of comorbidities that are likely to increase their risk of cardiovascular disease (CVD), making it more difficult to manage. In 2016, a tobacco ban began to be implemented across prisons in England and Wales, UK. This study aims to measure the effect of the tobacco ban on predicted cardiovascular risk for those quitting smoking on admission to prison., Design/methodology/approach: Using data from a prevalence study of CVD in prisons, the authors have assessed the effect of the tobacco ban on cardiovascular risk, using predicted age to CVD event, ten-year CVD risk and heart age, for those who previously smoked and gave up on admission to prison., Findings: The results demonstrate measurable health gains across all age groups with the greatest gains found in those aged 50 years and older and who had been heavy smokers. Quitting smoking on admission to prison led to a reduced heart age of between two and seven years for all participants., Originality/value: The data supports tobacco bans in prisons as a public health measure to reduce risk of CVD. Interventions are needed to encourage maintenance of smoking cessation on release from prison for the full health benefits to be realised., (© Emerald Publishing Limited.)
- Published
- 2022
- Full Text
- View/download PDF
9. Phase II multicentre, double-blind, randomised trial of ustekinumab in adolescents with new-onset type 1 diabetes (USTEK1D): trial protocol.
- Author
-
Gregory JW, Carter K, Cheung WY, Holland G, Bowen-Morris J, Luzio S, Dunseath G, Tree T, Yang JHM, Marwaha A, Ali MA, Bashir N, Hutchings HA, Fegan GW, Stenson R, Hiles S, Marques-Jones S, Brown A, Tatovic D, and Dayan C
- Subjects
- Adolescent, C-Peptide, Clinical Trials, Phase II as Topic, Double-Blind Method, Humans, Insulin, Multicenter Studies as Topic, Randomized Controlled Trials as Topic, Treatment Outcome, Diabetes Mellitus, Type 1 drug therapy, Ustekinumab therapeutic use
- Abstract
Introduction: Most individuals newly diagnosed with type 1 diabetes (T1D) have 10%-20% of beta-cell function remaining at the time of diagnosis. Preservation of residual beta-cell function at diagnosis may improve glycaemic control and reduce longer-term complications.Immunotherapy has the potential to preserve endogenous beta-cell function and thereby improve metabolic control even in poorly compliant individuals. We propose to test ustekinumab (STELARA), a targeted and well-tolerated therapy that may halt T-cell and cytokine-mediated destruction of beta-cells in the pancreas at the time of diagnosis., Methods and Analysis: This is a double-blind phase II study to assess the safety and efficacy of ustekinumab in 72 children and adolescents aged 12-18 with new-onset T1D.Participants should have evidence of residual functioning beta-cells (serum C-peptide level >0.2nmol/L in the mixed-meal tolerance test (MMTT) and be positive for at least one islet autoantibody (GAD, IA-2, ZnT8) to be eligible.Participants will be given ustekinumab/placebo subcutaneously at weeks 0, 4 and 12, 20, 28, 36 and 44 in a dose depending on the body weight and will be followed for 12 months after dose 1.MMTTs will be used to measure the efficacy of ustekinumab for preserving C-peptide area under the curve at week 52 compared with placebo. Secondary objectives include further investigations into the efficacy and safety of ustekinumab, patient and parent questionnaires, alternative methods for measuring insulin production and exploratory mechanistic work., Ethics and Dissemination: This trial received research ethics approval from the Wales Research Ethics Committee 3 in September 2018 and began recruiting in December 2018.The results will be disseminated using highly accessed, peer-reviewed medical journals and presented at conferences., Trial Registration Number: ISRCTN14274380., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.)
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.